BJ
LCTX icon

BlackRock Japan’s Lineage Cell Therapeutics LCTX Stock Holding History

BlackRock Japan’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,387
Closed -$12K – 1344
2014
Q1 		$12K Buy
+4,387
New +$12.9K ﹤0.01% 1327

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

BlackRock Japan's LCTX Position: Q2 2014 in Review

BlackRock Japan sold out of Lineage Cell Therapeutics (LCTX) in Q2 2014, closing a stake of 4,387 shares — an estimated $12K sold.

BlackRock Japan first reported a position in LCTX in Q1 2014 and held it in 1 quarter. The position peaked at $12K in Q1 2014. 62 funds tracked by Wall St. Rank hold LCTX as of Q2 2014.

  • BlackRock Japan reported no remaining Lineage Cell Therapeutics position as of Q2 2014 after selling out during the quarter.
  • BlackRock Japan sold 4,387 Lineage Cell Therapeutics shares in Q2 2014, an estimated $12K.
  • BlackRock Japan first reported a position in Lineage Cell Therapeutics in Q1 2014 and held it in 1 quarter.
  • BlackRock Japan's Lineage Cell Therapeutics position peaked at $12K in Q1 2014.
  • 62 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2014.

Based on BlackRock Japan's 13F filing for Q2 2014, filed 6 Aug 2014.